Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021742 | 0.90 | FFAR1 (0.42) | FFAR1SRD5A2FFAR4LMNA | |
| SCHEMBL14021748 | 0.90 | FFAR1 (0.47) | FFAR1SRD5A2FFAR4 | |
| Hydrochloric Acid SCHEMBL4596886 | 0.88 | FFAR1 (0.46) | FFAR1SRD5A2FFAR4 | |
| Hydrochloric Acid SCHEMBL4597540 | 0.88 | FFAR1 (0.41) | FFAR1SRD5A2FFAR4LMNA | |
| SCHEMBL14021733 | 0.86 | HDAC1 (0.43) | FFAR1KDM4E | |
| SCHEMBL14021677 | 0.85 | FFAR1 (0.57) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL14115836 | 0.85 | FFAR1 (0.57) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4882215 | 0.85 | HDAC1 (0.43) | FFAR1KDM4E | |
| Hydrochloric Acid SCHEMBL4596957 | 0.84 | FFAR1 (0.56) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 | |
| SCHEMBL14045409 | 0.82 | FFAR1 (0.54) | FFAR1SRD5A2FFAR4LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | claimed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | claimed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1907352-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007005774-A9 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007005774-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | FFAR1 14/4885SRD5A2 2125/4885FFAR4 13/4885 |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | FFAR1 14/4885SRD5A2 2125/4885FFAR4 13/4885 |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | GPR119, AADAT, FABP4 | FFAR1 14/4885SRD5A2 2125/4885FFAR4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.